Ascentage Pharma Share Price Today

Citigroup initiates coverage on Ascentage Pharma with Buy rating

Citigroup initiated coverage on Ascentage Pharma Group. Analyst Yigal Nochomovitz assigned a Buy rating. Price target set at $46 per share.

Ascentage Pharma revenue beats estimates; cash runway affirmed to 2027

Revenue grew 29.3% YoY to US$44.5 million, beating consensus of US$24.1 million. Net loss widened to US$120.4 million driven by 32% rise in R&D expenses. Management reaffirmed cash runway through end of 2027 despite higher burn. Lisaftoclax passed initial NRDL review; GLORA-2 enrollment complete. New leadership appointed to drive global commercialization efforts.

Ascentage Pharma Q2 Results: Unaudited interim data due August 19

Ascentage Pharma Group International will report its unaudited interim results for the first half of 2026 on August 19, 2026, at 7:00 am EDT. The company corrected the time from an earlier 9:00 am EDT notice. Management will host English and Mandarin investor webcasts on August 19 and 20, 2026, to discuss the financial performance and business updates related to its oncology pipeline, including trials for Olverembatinib and Lisaftoclax.

Ascentage Pharma appoints Miyara, Ziegler to lead global expansion

Ascentage Pharma Group International named Faiçal Miyara as CBO and Jim Ziegler as CCO to lead global business development and US commercialization. The moves support the company's advancing Phase III pipeline for oncology therapies olverembatinib and lisaftoclax.

Ascentage Pharma CEO Dr. Dajun Yang Ranks No. 3 on Medicine Maker Power List 2026

Ascentage Pharma Group International’s Chairman and CEO Dr. Dajun Yang has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition coincides with the company’s advancement of multiple global Phase III trials for olverembatinib and lisaftoclax, several of which are cleared by the FDA and EMA. Ascentage Pharma, listed on NASDAQ and HKEX, continues to expand its global footprint through strategic partnerships and dual primary listings.

Ascentage Pharma presents clinical updates at EHA2026 Congress

Ascentage Pharma Group International presented 17 clinical updates at EHA2026, highlighting data on olverembatinib and lisaftoclax. Olverembatinib showed deep responses in CML and Ph+ ALL, while lisaftoclax demonstrated promise in CLL/SLL and myeloid neoplasms. The studies support the potential of these assets as treatment options for resistant or refractory hematologic malignancies.